M. Gore

3.2k total citations
94 papers, 2.4k citations indexed

About

M. Gore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M. Gore has authored 94 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in M. Gore's work include Renal cell carcinoma treatment (31 papers), Ovarian cancer diagnosis and treatment (21 papers) and Cancer Genomics and Diagnostics (17 papers). M. Gore is often cited by papers focused on Renal cell carcinoma treatment (31 papers), Ovarian cancer diagnosis and treatment (21 papers) and Cancer Genomics and Diagnostics (17 papers). M. Gore collaborates with scholars based in United Kingdom, United States and Netherlands. M. Gore's co-authors include Roger A’Hern, J. Moore, Timothy Perren, Jean‐Paul Guastalla, G. Favalli, Ángel J. Lacave, Giorgio Bolis, Giovanna Scarfone, I Hudson and Jaap Verweij and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

M. Gore

92 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Gore United Kingdom 29 1.1k 816 609 503 448 94 2.4k
Lindsey Gumbrell United Kingdom 17 1.3k 1.2× 932 1.1× 564 0.9× 321 0.6× 392 0.9× 24 2.7k
Diana N. Ionescu Canada 26 893 0.8× 625 0.8× 1.1k 1.9× 558 1.1× 304 0.7× 78 2.7k
Joseph Kerger Belgium 26 1.5k 1.4× 382 0.5× 606 1.0× 242 0.5× 799 1.8× 69 2.4k
Roshan Agarwal United Kingdom 30 1.1k 1.0× 1.7k 2.1× 479 0.8× 667 1.3× 452 1.0× 61 3.8k
Jean‐Paul Guastalla France 31 2.2k 2.1× 621 0.8× 495 0.8× 621 1.2× 521 1.2× 109 3.7k
Atsuhiko Sakamoto Japan 28 1.0k 0.9× 618 0.8× 397 0.7× 929 1.8× 648 1.4× 126 3.5k
Sidney Scudder United States 20 603 0.6× 406 0.5× 316 0.5× 578 1.1× 281 0.6× 49 1.9k
Andrew R. Clamp United Kingdom 24 739 0.7× 734 0.9× 276 0.5× 623 1.2× 222 0.5× 116 2.0k
Wayne Rackoff United States 19 1.0k 1.0× 766 0.9× 945 1.6× 286 0.6× 270 0.6× 35 2.9k

Countries citing papers authored by M. Gore

Since Specialization
Citations

This map shows the geographic impact of M. Gore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Gore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Gore more than expected).

Fields of papers citing papers by M. Gore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Gore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Gore. The network helps show where M. Gore may publish in the future.

Co-authorship network of co-authors of M. Gore

This figure shows the co-authorship network connecting the top 25 collaborators of M. Gore. A scholar is included among the top collaborators of M. Gore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Gore. M. Gore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coward, Jermaine, et al.. (2013). A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology. British Journal of Cancer. 109(9). 2295–2300. 68 indexed citations
2.
Lorigan, Paul, Jeff Sosman, J.B.A.G. Haanen, et al.. (2010). Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs). Annals of Oncology. 21. 5 indexed citations
3.
Mickisch, G., M. Gore, Bernard Escudier, et al.. (2009). Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer. 102(1). 80–86. 54 indexed citations
4.
Am, Eggermont, Stefan Suciu, Mario Santinami, et al.. (2008). EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.. The Lancet. 12. 117–126. 77 indexed citations
5.
Brooke, Antonia, Norman Taylor, J. H. Shepherd, et al.. (2006). A Novel Point Mutation in P450c17 (CYP17) Causing Combined 17α-Hydroxylase/17,20-Lyase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 91(6). 2428–2431. 34 indexed citations
6.
Stebbing, Justin & M. Gore. (2001). The current status of interferon‐α treatment in advanced renal cancer. British Journal of Urology. 87(7). 599–601. 8 indexed citations
7.
Keilholz, Ulrich, C.J.A. Punt, M. Gore, et al.. (2000). Dacarbazine, cisplatin and IFN-alpha with or without IL-2 in advanced melanoma (EORTC trial 18951). Annals of Oncology. 11. 4. 15 indexed citations
8.
Piccart, Martine, Andreas du Bois, M. Gore, et al.. (2000). A new standard of care for treatment of ovarian cancer. European Journal of Cancer. 36(1). 10–12. 24 indexed citations
9.
10.
Powles, R, Noopur Raje, S Milan, et al.. (1997). Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplantation. 20(6). 435–443. 55 indexed citations
11.
Rigg, Anne, David Cunningham, M. Gore, et al.. (1997). A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. British Journal of Cancer. 75(1). 101–105. 12 indexed citations
12.
Holloway, B., et al.. (1997). The significance of paracardiac lymph node enlargement in ovarian cancer. Clinical Radiology. 52(9). 692–697. 48 indexed citations
13.
Modjtahedi, Helmout, Tamas Hickish, Margery Nicolson, et al.. (1996). Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. British Journal of Cancer. 73(2). 228–235. 82 indexed citations
14.
Cunningham, David, John Zalcberg, I E Smith, et al.. (1996). ‘Tomudex’ (ZD1694) : A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Annals of Oncology. 7(2). 179–182. 45 indexed citations
15.
Gore, M., et al.. (1996). Transformation of residual mature ovarian teratoma to adenocarcinoma 10 years after initial treatment. Clinical Oncology. 8(2). 125–126. 5 indexed citations
16.
Gore, M., Vincent Lévy, Gordon Rustin, et al.. (1995). Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer. 72(4). 1016–1019. 45 indexed citations
17.
Hill, Mark, S Milan, David Cunningham, et al.. (1995). Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity.. Journal of Clinical Oncology. 13(2). 387–395. 37 indexed citations
18.
Gore, M., et al.. (1994). The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. European Journal of Cancer. 30(3). 329–333. 19 indexed citations
19.
Calvert, A H, et al.. (1991). Phase II trial of trimelamol in refractory ovarian cancer. British Journal of Cancer. 63(2). 311–313. 8 indexed citations
20.
Gore, M., AH Calvert, & IE Smith. (1987). A PHASE-I HIGH-DOSE ESCALATION STUDY OF CARBOPLATIN. UCL Discovery (University College London). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lindsey Gumbrell Breakdown of academic impact, for papers by Diana N. Ionescu Breakdown of academic impact, for papers by Joseph Kerger Breakdown of academic impact, for papers by Roshan Agarwal Breakdown of academic impact, for papers by Jean‐Paul Guastalla Breakdown of academic impact, for papers by Atsuhiko Sakamoto Breakdown of academic impact, for papers by Sidney Scudder Breakdown of academic impact, for papers by Andrew R. Clamp Breakdown of academic impact, for papers by Wayne Rackoff
Rankless by CCL
2026